AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company ...
Q4 2025 earnings call highlights: record sales, Skyrizi/Rinvoq momentum, 2026 guidance ($67B) and risks—read key takeaways.
The legislation will impose new restrictions on pharmacy benefit managers, giant companies like CVS Caremark, Optum Rx and ...
AbbVie Inc. forecast 2026 profits above Wall Street’s expectations.
The choice between the two might come down to each investor's goals and risk tolerance.
By diving deeper into the dynamics of high-cost claims, employers can uncover valuable insights that pave the way for smart, ...
As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corp. (INTC) and The Boeing Company (BA), as well as a micro-cap stock Tandy Leather ...
CVS Health outlined its efforts to decrease prior authorizations, reduce hospital readmissions and emergency room visits and ...
Johnson & Johnson ( JNJ) Q4 2025 Earnings Call January 21, 2026 8:30 AM EST Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] This ...
Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results